Author of

• 11905

  +

  P2.20 - Poster Session 2 - Early Detection and Screening (ID 173)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Imaging, Staging & Screening
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11916

    +

    P2.20-011 - A prospective clinical study evaluating stage dependent sputum micro-RNA expression profiles for the detection of non-small cell lung cancer (ID 3440)

    09:30 - 09:30  |  Author(s): J.O. Kim
    • Abstract

    Background
    Lung Cancer accounts for the greatest cancer related mortality worldwide. To date, no effective screening tool for Non-Small Cell Lung Cancer (NSCLC) exists. For patients with operable stage IA NSCLC, the 5-year survival can be as high as 80%. Early detection is crucial in improving long-term survival. MicroRNAs (miRNAs), a class of short noncoding RNA molecules. miRNA expression in biological fluid samples such as sputum has shown promise as a potential means of detecting NSCLC. Our objective was to utilize an efficient, cost-effective panel consisting of 3 miRNAs (miR-21, miR-210 and miR-372) for prospective validation as a potential means of accurately detecting NSCLC. This panel was selected based on retrospective analysis of 11 miRNAs our group had previously undertaken using separate NSCLC and control cohorts.

    Methods
    21 early NSCLC (≤ Stage II) patients, 22 advanced NSCLC (≥ Stage III) patients and 10 control subjects were prospectively accrued. A single sputum sample was obtained through spontaneous expectoration from each study participant. Detailed study participant and tumor characteristics were obtained. miR-21, miR-210 and miR-372 expression was conducted on each sputum sample and normalized to an endongenous control (U6) relative to a MRC-5 reference sample, using RNA reverse transcription and Quantitative real-time Polymerase Chain Reaction (RT-qPCR). Statistical evaluation consisted of unsupervised hierarchical cluster analysis of the experimental-normalized miRNA expression profiles using within-group linkage.

    Results
    The median ages of the early NSCLC cases, advanced NSCLC cases and controls were 68, 68 and 58.5 respectively. The majority of the early and advanced NSCLC patients had smoking histories (>90%). 60% of the controls had smoking histories. Mean tumor size (± standard deviation) for early and advanced NSCLC cases were 3.4 cm (± 2.1 cm) and 4.8 cm (± 1.7 cm) respectively. Adenocarcinoma and squamous cell carcinoma comprised 62% and 23.8% of early NSCLC cases. Adenocarcinoma and squamous cell carcinoma comprised 45.5% and 22.7% of advanced NSCLC cases. Comparing early NSCLC to controls, the use of miR-21, miR-210 and miR372 expression yielded a diagnostic sensitivity of 66.7% and a specificity of 90.0%. Advanced NSCLC patients had an improved sensitivity of 81.8% with the same specificity of 90.0%.

    Conclusion
    The utilization of miR-21, miR-210 and miR372 sputum expression might provide a sensitive and specific means of detecting NSCLC. The potential linkage between their expression and NSCLC stage may account for the higher sensitivity observed in the advanced NSCLC group. Future use of this promising panel on a larger population will be required to establish its potential application as a screening tool.